Alkaline Phosphatase in Metastatic Castration-Resistant Prostate Cancer: Reassessment of an Older Biomarker
Authors:
Open Access
- 21 June 2018
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 14 (24) , 2543-2556
Abstract
Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.Keywords
Funding Information
- Bristol-Myers Squibb
- Janssen-Cilag
- Novartis
- Merck Sharp & Dohme
- Roche
- Oncoinvent AS
- Bayer HealthCare Pharmaceuticals
- Takeda
- Janssen
- Astellas
- AstraZeneca
- Daiichi-Sankyo
- Pfizer
- Taiho
- Nihon-Kayaku
This publication has 92 references indexed in Scilit:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trialAnnals of Oncology, 2013
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Prostate Cancer Cells and Bone Stromal Cells Mutually Interact with Each Other through Bone Morphogenetic Protein-mediated SignalsJournal of Biological Chemistry, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Cancer to bone: a fatal attractionNature Reviews Cancer, 2011
- Prostate cancer as a model for tumour immunotherapyNature Reviews Immunology, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009